Literature DB >> 15953491

Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.

Stefan Leucht1, Raymonde Busch, Johannes Hamann, Werner Kissling, John M Kane.   

Abstract

BACKGROUND: A recent meta-analysis rejected the "delayed onset of antipsychotic action hypothesis" that had been described in textbooks for decades. Since meta-analyses are prone to a number of methodological problems, we attempted a replication by a) using a large database of individual patient data rather than meta-analysis, b) including another antipsychotic and c) extending the analysis from four weeks to one year.
METHODS: We pooled the data of seven randomized trials involving amisulpride. The data included 1708 patients with schizophrenia and positive symptoms and we examined the incremental percentage Brief Psychiatric Rating Scale (BPRS) reduction over time.
RESULTS: The "early onset of antipsychotic action hypothesis" was confirmed, as the reduction of overall and positive symptoms until week two was larger than the additional reduction until week four (p<.0001). Furthermore, in a subset with long-term data (n=748) approximately 68% of the mean BPRS change at one year was already achieved at four weeks in the observed cases.
CONCLUSIONS: A substantial amount of the antipsychotic drug effect seems to occur during the first weeks of treatment. Subsequent analyses are needed to establish how long an antipsychotic should be tried before it is considered ineffective and alternative strategies implemented.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15953491     DOI: 10.1016/j.biopsych.2005.02.023

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  51 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  The "delayed onset" of antipsychotic action--an idea whose time has come and gone.

Authors:  Ofer Agid; Phillip Seeman; Shitij Kapur
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

Review 4.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

Review 5.  Unanswered questions in schizophrenia clinical trials.

Authors:  John M Kane; Stefan Leucht
Journal:  Schizophr Bull       Date:  2008-01-16       Impact factor: 9.306

6.  Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

Authors:  Robert P McMahon; Deanna L Kelly; Douglas L Boggs; Lan Li; Qiaoyan Hu; John M Davis; William T Carpenter
Journal:  Schizophr Bull       Date:  2008-01-08       Impact factor: 9.306

7.  Trajectories and antecedents of treatment response over time in early-episode psychosis.

Authors:  Stephen Z Levine; J Rabinowitz
Journal:  Schizophr Bull       Date:  2008-10-09       Impact factor: 9.306

8.  Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.

Authors:  Bruce J Kinon; Lei Chen; Haya Ascher-Svanum; Virginia L Stauffer; Sara Kollack-Walker; Wei Zhou; Shitij Kapur; John M Kane
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

9.  Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits.

Authors:  Luke E Sebel; Steven M Graves; C Savio Chan; D James Surmeier
Journal:  Neuropsychopharmacology       Date:  2016-08-31       Impact factor: 7.853

10.  Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.

Authors:  Douglas E Faries; Allen W Nyhuis; Haya Ascher-Svanum
Journal:  Cost Eff Resour Alloc       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.